What's Happening?
The U.S. Office of Personnel Management (OPM) has announced that the Federal Benefits Open Season for the 2027 plan year will run from November 9 to December 14, 2026. During this period, federal employees can review and make changes to their health,
dental, and vision benefits. OPM reports that the average enrollee share of Federal Employees Health Benefits (FEHB) premiums will increase by 10.9% in 2027, a slight decrease from the 12.3% increase in 2026. For the Postal Service Health Benefits (PSHB) program, the average enrollee share will rise by 8.2%. Overall average FEHB premiums are projected to increase by 9.3%. Additionally, OPM has introduced a new requirement for the 2027 plan year: anyone adding a new family member to FEHB or PSHB coverage during Open Season must submit supporting documentation to verify eligibility, a measure based on the FEHB Protection Act of 2025. The agency attributes these premium increases primarily to rising prices and increased utilization of healthcare services, including inpatient, physician, outpatient, surgical services, behavioral and mental health care, and prescription drug spending.
Why It's Important?
The announced premium increases will directly impact the financial well-being of approximately 7.9 million federal employees, Postal Service employees, annuitants, and their eligible family members covered by FEHB and PSHB. The 10.9% average increase in enrollee share for FEHB means federal workers will bear a larger portion of their healthcare costs, potentially affecting household budgets. The new documentation requirement for adding family members aims to enhance program integrity and ensure that only eligible individuals receive benefits, which could streamline administrative processes but also adds a new step for enrollees. These changes reflect broader trends in the U.S. healthcare industry, where rising costs for services and prescription drugs continue to drive up insurance premiums. OPM's detailed breakdown of cost drivers, including GLP-1 medications and specialty drugs, highlights the significant influence of pharmaceutical advancements and utilization on overall healthcare expenditures. This annual Open Season is a critical period for federal employees to assess their healthcare needs against evolving costs and coverage options.
What's Next?
Federal employees will need to carefully review their current health, dental, and vision plans during the Open Season from November 9 to December 14, 2026, to determine if their existing coverage remains the best option given the premium increases and any changes in their personal circumstances. Those planning to add new family members to their FEHB or PSHB plans must prepare to submit the required supporting documentation to OPM for eligibility verification. OPM provides online tools, such as the FEHB Plan Comparison Tool and FEDVIP Plan Comparison Tool, to assist employees in evaluating their choices. While existing health, dental, and vision coverage generally continues automatically if no changes are made, participants in the Federal Flexible Spending Account Program (FSAFEDS) must re-enroll annually. The Postal Service Health Benefits System is also launching a redesigned Enrollee Portal during Open Season, which may impact how PSHB participants manage their benefits. Employees are encouraged to consult their employing office's benefits officer for specific guidance.
Beyond the Headlines
The consistent rise in federal employee health insurance premiums reflects a national challenge in managing healthcare costs, impacting both public and private sectors. This trend could lead to increased pressure on federal employees' disposable income, potentially influencing their financial planning and overall job satisfaction. The new documentation requirement, while aimed at preventing fraud and ensuring eligibility, also signifies a broader move towards stricter oversight in federal benefit programs. This could set a precedent for other government-sponsored benefits, emphasizing accountability and verification. The specific mention of GLP-1 medications and specialty drugs as cost drivers points to the growing influence of advanced pharmaceutical treatments on healthcare economics. As these high-cost therapies become more prevalent, their impact on insurance premiums will likely continue, prompting ongoing discussions about drug pricing, coverage, and access within federal and private health plans. This situation underscores the continuous need for policy adjustments and innovative solutions to address the escalating costs of healthcare in the U.S.
